Inhibition of the IKKβ/NFκB signaling pathway has been shown to contribute to the regression of liver fibrosis and the improvement of metabolic-associated fatty liver disease (MAFLD) [18,19,20]. This evidence concerns the gene NFKB1 and Hepatic fibrosis.